Seeking Alpha

Dendreon (DNDN +1.2%) preliminary adjusted FQ4 net product revenues +5% Q/Q to $81.6M vs...

Dendreon (DNDN +1.2%) preliminary adjusted FQ4 net product revenues +5% Q/Q to $81.6M vs consensus of $83.66M. Community sales hit record, with urology +25%, oncology +4%. Community accounts represent 71% of total sales, up from 58% in Q4 2011. Dendreon benefits from the increased use of its Provenge prostate cancer drug in community oncology and urology settings. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs